Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) aims to invest EGP 2 billion in new drug acquisitions, according to a bourse disclosure.
Rameda also highlighted that the issued capital of its subsidiary, Glow, was initially determined as EGP 250,000. The paid-up capital stands at EGP 25,000, while the authorised capital is EGP 2.50 million.
Glow will reflect on the EGX-listed company’s statements for the period ending on 31 December 2025.
